Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial

Antonio J. Vallejo-Vaz, Rana Fayyad, S. Matthijs Boekholdt, G. Kees Hovingh, John J. Kastelein, Shari Melamed, Philip Barter, David D. Waters, Kausik K. Ray

Research output: Contribution to journalArticleAcademicpeer-review

116 Citations (Scopus)

Abstract

BACKGROUND: Mendelian randomization data suggest that the genetic determinants of lifetime higher triglyceride-rich lipoprotein-cholesterol (TRL-C) are causally related to cardiovascular disease and therefore a potential therapeutic target. The relevance of TRL-C among patients receiving statins is unknown. We assessed the relationship between TRL-C and cardiovascular risk, and whether this risk was modifiable among patients receiving statins in the TNT trial (Treating to New Targets).
Original languageEnglish
Pages (from-to)770-781
JournalCirculation
Volume138
Issue number8
DOIs
Publication statusPublished - 2018

Cite this